title: Sentinel lymph node identification using superparamagnetic iron oxide particles versus radioisotope: The French Sentimag feasibility trial.
abstract: OBJECTIVE
  The French Sentimag feasibility trial evaluated a new method for the localization of breast cancer sentinel lymph node (SLN) using Sienna+®, superparamagnetic iron oxide particles, and Sentimag® detection in comparison to the standard technique (isotopes ± blue dye).
  
  
  METHODS
  We conducted a prospective multicentric paired comparison trial on 115 patients. SLN localization was performed using both the magnetic technique and the standard method. Detection rate and concordance between magnetic and standard tracers were calculated. Post-operative complications were assessed after 30 days.
  
  
  RESULTS
  Results are based on 108 patients. SLN identification rate was 98.1% [93.5-99.8] for both methods, 97.2% [92.1-99.4] for Sienna+® and 95.4% [89.5-98.5] for standard technique. A mean of 2.1 SLNs per patient was removed. The concordance rate was 99.0% [94.7-100.0%] per patient and 97.4% [94.1-99.2] per node. Forty-six patients (43.4%) had nodal involvement. Among involved SLNs, concordance rate was 97.7% [88.0-99.9] per patient and 98.1% [90.1-100.0] per node.
  
  
  CONCLUSIONS
  This new magnetic tracer is a feasible method and a promising alternative to the isotope. It could offer benefits for ambulatory surgery or sites without nuclear medicine departments. J. Surg. Oncol. 2016;113:501-507. © 2016 Wiley Periodicals, Inc.
authors.affiliation: Department of Senology, Centre Oscar Lambret, Lille Cedex, France.
authors.forename: Jean-Louis
authors.initials: JL
authors.lastname: Houpeau
authors.affiliation: Department of Senology, Centre Oscar Lambret, Lille Cedex, France.
authors.forename: Marie-Pierre
authors.initials: MP
authors.lastname: Chauvet
authors.affiliation: Department of Surgical Oncology, Institut de Cancérologie de Lorraine-Alexis Vautrin, Vandoeuvre les Nancy, France.
authors.forename: François
authors.initials: F
authors.lastname: Guillemin
authors.affiliation: Department of Surgical Oncology, Centre Eugène Marquis, Rennes Cedex, France.
authors.forename: Cécile
authors.initials: C
authors.lastname: Bendavid-Athias
authors.affiliation: Department of Surgical Oncology, Institut Claudius Regaud, Toulouse Cedex, France.
authors.forename: Hélène
authors.initials: H
authors.lastname: Charitansky
authors.affiliation: Department of Biostatistic, Centre Oscar Lambret, Lille Cedex, France.
authors.forename: Andrew
authors.initials: A
authors.lastname: Kramar
authors.affiliation: Department of Senology, Centre Oscar Lambret, Lille Cedex, France.
authors.forename: Sylvia
authors.initials: S
authors.lastname: Giard
mesh_terms: D000368:Aged; D001943:Breast Neoplasms / Q000473:pathology / Q000601:surgery*; D002277:Carcinoma / Q000556:secondary / Q000601:surgery*; D003287:Contrast Media; D003911:Dextrans; D005240:Feasibility Studies; D005260:Female; D005602:France; D006801:Humans; D058185:Magnetite Nanoparticles; D060306:Magnetometry / Q000295:instrumentation*; D008875:Middle Aged; D011446:Prospective Studies; D019275:Radiopharmaceuticals; D021701:Sentinel Lymph Node Biopsy / Q000379:methods*
chemical_list: D003287:Contrast Media; D003911:Dextrans; D058185:Magnetite Nanoparticles; D019275:Radiopharmaceuticals; C065507:ferumoxides
keywords: invasive breast cancer; nanoparticles; sentimag®; sentinel lymph node biopsy; sienna®; superparamagnetic iron oxide (SPIO)